Research abstract

Article abstract


Nature Biotechnology 26, 443 - 452 (2008)
Published online: 20 February 2008 | doi:10.1038/nbt1393

Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo

Evert Kroon1, Laura A Martinson1, Kuniko Kadoya1, Anne G Bang1, Olivia G Kelly1, Susan Eliazer1, Holly Young1, Mike Richardson1, Nora G Smart1, Justine Cunningham1, Alan D Agulnick1, Kevin A D'Amour1, Melissa K Carpenter1 & Emmanuel E Baetge1


Development of a cell therapy for diabetes would be greatly aided by a renewable supply of human beta-cells. Here we show that pancreatic endoderm derived from human embryonic stem (hES) cells efficiently generates glucose-responsive endocrine cells after implantation into mice. Upon glucose stimulation of the implanted mice, human insulin and C-peptide are detected in sera at levels similar to those of mice transplanted with approx3,000 human islets. Moreover, the insulin-expressing cells generated after engraftment exhibit many properties of functional beta-cells, including expression of critical beta-cell transcription factors, appropriate processing of proinsulin and the presence of mature endocrine secretory granules. Finally, in a test of therapeutic potential, we demonstrate that implantation of hES cell–derived pancreatic endoderm protects against streptozotocin-induced hyperglycemia. Together, these data provide definitive evidence that hES cells are competent to generate glucose-responsive, insulin-secreting cells.

Top
  1. Novocell, Inc., 3550 General Atomics Ct., San Diego, California 92121, USA.


MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Toward a renewable source of pancreatic β-cells

Nature Biotechnology News and Views (01 Apr 2008)

Towards cell therapy for diabetes

Nature Biotechnology News and Views (01 Dec 2006)

See all 6 matches for News And Views

Extra navigation

natureproducts


ADVERTISEMENT